Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

The Lancet Oncology

Volumn 10, Issue 9, 2009, Pages 855-864

  Finke, Jürgen ^a   Bethge, Wolfgang A ^b   Schmoor, Claudia ^a   Ottinger, Hellmut D ^c   Stelljes, Matthias ^d   Zander, Axel R ^e   Volin, Liisa ^f   Ruutu, Tapani ^f   Heim, Dominik A ^g   Schwerdtfeger, Rainer ^h   Kolbe, Karin ⁱ   Mayer, Jiri ^j   Maertens, Johan A ^k   Linkesch, Werner ^l   Holler, Ernst ^m   Koza, Vladimir ⁿ   Bornhäuser, Martin ^o   Einsele, Hermann ^p   Kolb, Hans Jochem ^q   Bertz, Hartmut ^a   Egger, Matthias ^a   Grishina, Olga ^a   Socié, Gérard ^r   Muller C H ^s   Scheele, J ^s   Schilling, B ^s   Kaufmann, M ^s   Tostmann, R ^s   Kollmer, A ^s   Nuss, S ^s   Wenig, C ^s   Muller R K ^s   Hantschel M ^s   Trenschel, R ^s   Kroger N M ^s   Ayuketang, F A ^s   Wolschke, C ^s   Kaltenhauser J ^s   Stubig T ^s   Taube, R H ^s   Thomas, S ^s   Ullmann, A ^s   Schulze Bergkamen, A ^s   Hahn, J ^s   Reibke, R ^s   Wandt, H ^s   Schaefer Eckart, K ^s   Gluckman, E ^s   Esperou, H ^s   Robin, M ^s   Michallet, M ^s   Nicolini, F ^s   Buzyn, A ^s   Rubio, M T ^s   Yakoub Agha, I ^s   Jouet, J P ^s   Petillon, M O ^s   Bordigoni, P ^s   Clement, L ^s   Salmon, A ^s   Feugier, P ^s   Juvonen, E ^s   Nihtinen, A ^s   Remes, K ^s   Putkonen, M ^s   Itala M ^s   Kauppila, M ^s   Krejci, M ^s   Brychtova Y ^s   Karas, M ^s   Voglova, J ^s   Lebavy, J ^s   Zak, P ^s   Gratwohl, A ^s   Passweg, J ^s   Arber, C ^s   Tsakiris, A ^s   Reitter, S ^s   Staber, P B ^s   Lutz, D ^s   Krieger, O ^s   Theunissen, K ^s   Boogaerts, M ^s   Verhoef, G ^s   Rowe, J ^s   Rosenvald Zuckermann, T ^s   Shapira, M ^s   Or, R ^s   Resnik, I ^s   Nagler, A ^s   Shimoni, A ^s   Yerushalmi, R ^s   Sierra, J ^s   Valcarcel, D ^s   Perez Simon J A ^s   Astorga, M ^s   Bosi, A ^s   Guidi, S ^s   Hollander N ^s   Jahnchen E ^s   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY HOSPITAL GRAZ   (Austria)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^p UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^q LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^r SAINT LOUIS HOSPITAL   (France)

^s Hôpital Saint Louis ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ANAPHYLACTIC SHOCK; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; BREAST DISEASE; CANDIDIASIS; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; EAR DISEASE; EYE DISEASE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INCIDENCE; INJURY; INTOXICATION; KIDNEY DISEASE; KIDNEY FAILURE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL DISEASE; MYCOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PARASITOSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; SURVIVAL; THORAX DISEASE; VASCULAR DISEASE; VIRUS INFECTION;

EID: 69249193742     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70225-6     Document Type: Article

References (30)

1. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
2. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
3. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 27 (2009) 1644-1652
4. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
5. Lee S.J., Zahrieh D., Alyea E.P., et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 100 (2002) 2697-2702
6. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
7. Finke J., Schmoor C., Lang H., Potthoff K., and Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 21 (2003) 506-513
8. Zander A.R., Kroger N., Schleuning M., et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 32 (2003) 355-361
9. Schleuning M., Gunther W., Tischer J., Ledderose G., and Kolb H.J. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 32 (2003) 243-250
10. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
11. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-956
12. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
13. Fine J.P., and Gray R.J. A proportional hazards model for subdistribution of competing risk. J Am Stat Assoc 94 (1999) 496-609
14. Makuch R.W. Adjusted survival curve estimation using covariates. J Chronic Dis 35 (1982) 437-443
15. Rosthoj S., Andersen P.K., and Abildstrom S.Z. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 74 (2004) 69-75
16. Latouche A., and Porcher R. Sample size calculations in the presence of competing risks. Stat Med 26 (2007) 5370-5380
17. Schulgen G., Olschewski M., Krane V., Wanner C., Ruf G., and Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 26 (2005) 386-396
18. Maraninchi D., Gluckman E., Blaise D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2 (1987) 175-178
19. Blaise D., Gravis G., and Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 341 (1993) 51-52
20. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
21. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 106 (2005) 3308-3313
22. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
23. Schmitz N., Beksac M., Bacigalupo A., et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 90 (2005) 643-648
24. Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108 (2006) 4288-4290
25. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95 (2000) 3702-3709
26. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 13 (2007) 1461-1468
27. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113 (2009) 4992-5001
28. Grullich C., Ziegler C., and Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transplant 15 (2009) 173-182
29. Weisdorf D., Bishop M., Dharan B., et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant 8 (2002) 213-220
30. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051